Sacubitril/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial

AIMS: In recent years, survival in patients with breast cancer has increased. Despite the improvement in outcomes of those patients, the risk of treatment‐related cardiotoxicity remains high, and its presence has been associated with a higher risk of treatment termination and thus lower therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Tajstra, Mateusz, Dyrbuś, Maciej, Rutkowski, Tomasz, Składowski, Krzysztof, Sosnowska‐Pasiarska, Barbara, Góźdź, Stanisław, Radecka, Barbara, Staszewski, Marek, Majsnerowska, Aleksandra, Myrda, Krzysztof, Nowowiejska‐Wiewióra, Alicja, Skoczylas, Ilona, Rymkiewicz, Igor, Niklewski, Tomasz, Nowak, Jolanta, Przybyłowski, Piotr, Gąsior, Mariusz, Jarząb, Michał
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Study Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567668/
https://www.ncbi.nlm.nih.gov/pubmed/37449716
http://dx.doi.org/10.1002/ehf2.14466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567668/
https://www.ncbi.nlm.nih.gov/pubmed/37449716
http://dx.doi.org/10.1002/ehf2.14466

Ejemplares similares